Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12277252 | 0.77 | ABL1 (0.47) | GRM5APPADORA2AADORA3ADORA1 | |
| SCHEMBL6202593 | 0.70 | HAO1 (0.48) | GRM5APP | |
| Diphenylacetylene SCHEMBL68254 | 0.67 | APP (1.00) | GRM5APP | |
| Diphenylacetylene SCHEMBL960609 | 0.67 | APP (1.00) | GRM5APP | |
| Diphenylacetylene SCHEMBL29188592 | 0.67 | APP (1.00) | GRM5APP | |
| SCHEMBL6289336 | 0.67 | GRM5 (0.50) | GRM5APP | |
| SCHEMBL17705931 | 0.66 | GRM5 (0.62) | GRM5APPADORA2A | |
| SCHEMBL9430361 | 0.65 | APP (0.48) | GRM5APP | |
| Diphenylacetylene SCHEMBL23754283 | 0.65 | APP (0.80) | GRM5APP | |
| Diphenylacetylene SCHEMBL28297812 | 0.65 | APP (0.80) | GRM5APPADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445503-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | GRM5 2925/4885APP 1779/4885ADORA2A 3335/4885 |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | GRM5 2934/4885APP 1739/4885ADORA2A 3299/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | GRM5 2934/4885APP 1739/4885ADORA2A 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.